OverviewSuggest Edit

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

HQActon, US

Latest Updates

Employees (est.) (Dec 2018)1,169(+37%)
Job Openings156
Revenue (FY, 2018)$563.8 M(+22%)
Share Price (Jan 2020)$191 (+2%)

Key People/Management at Insulet

Patrick Sullivan

Patrick Sullivan

Chairman of the Board and Chief Executive Officer
Aiman Abdel-Malek

Aiman Abdel-Malek

Senior Vice President, Advanced Technology and Engineering
Bret Christensen

Bret Christensen

Senior Vice President and Chief Commercial Officer
David Colleran

David Colleran

Senior Vice President, Secretary and General Counsel
Deborah Gordon

Deborah Gordon

Vice President, Investor Relations and Corporate Communications
Michael Levitz

Michael Levitz

Senior Vice President, Chief Financial Officer and Treasurer
Show more

Insulet Office Locations

Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 13 other locations
Acton, US (HQ)
100 Nagog Park
Billerica, US
600 Technology Park Dr #200
Charlotte, US
Charlotte, NC, USA
Chicago, US
Chicago, IL, USA
Columbus, US
Columbus, OH, USA
Denver, US
Denver, CO, USA
Show all (17)

Insulet Financials and Metrics

Insulet Revenue

Embed Graph
View revenue for all periods
Insulet's revenue was reported to be $563.82 m in FY, 2018

Revenue (Q3, 2019)


Gross profit (Q3, 2019)


Gross profit margin (Q3, 2019), %


Net income (Q3, 2019)


EBIT (Q3, 2019)


Market capitalization (21-Jan-2020)


Closing stock price (21-Jan-2020)


Cash (30-Sept-2019)



Insulet's current market capitalization is $11.7 b.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income


Depreciation and Amortization




Cash From Operating Activities

USDY, 2019


719.6 x


237.7 x

Financial Leverage

8.4 x
Show all financial metrics

Insulet Operating Metrics

FY, 2016

Patents Issued


Patents Pending

Show all operating metrics

Insulet Revenue Breakdown

Embed Graph

Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Insulet Online and Social Media Presence

Embed Graph

Insulet News and Updates

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

Why Is Insulet Stock Up More Than 15% Over The Last Month?

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger...

Medication Telemanagement Devices Market 2018 Global Analysis By Key Players – Abiogenix, Adherium, IA Collaborative, Insulet, MedFolio

Wiseguyreports.Com adds “Medication Telemanagement Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Wearable Medical Equipment Market to witness astonishing growth with Key Players Abbott Diabetes Care, Flextronics International, Insulet Corporation

HTF MI recently launched the Global Wearable Medical Equipment study with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. Posted via Industry Today. Follow us on Twitter @IndustryToday

Insulet Frequently Asked Questions

  • When was Insulet founded?

    Insulet was founded in 2000.

  • Who are Insulet key executives?

    Insulet's key executives are Patrick Sullivan, Aiman Abdel-Malek and Bret Christensen.

  • How many employees does Insulet have?

    Insulet has 1,169 employees.

  • What is Insulet revenue?

    Latest Insulet annual revenue is $563.8 m.

  • What is Insulet revenue per employee?

    Latest Insulet revenue per employee is $482.3 k.

  • Who are Insulet competitors?

    Competitors of Insulet include Tandem Diabetes Care, POPS! Diabetes Care and LifeScan.

  • Where is Insulet headquarters?

    Insulet headquarters is located at 100 Nagog Park, Acton.

  • Where are Insulet offices?

    Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 13 other locations.

  • How many offices does Insulet have?

    Insulet has 17 offices.